Sympathetic nervous system in heart failure

Circulation

Volumn 106, Issue 19, 2002, Pages 2417-2418

  Cohn, Jay N ^a  

^a UNIVERSITY OF MINNESOTA   (United States)

Author keywords

Editorials; Heart failure; Nervous system, sympathetic

Indexed keywords

ALPHA 1 ADRENERGIC RECEPTOR BLOCKING AGENT; ALPHA 2 ADRENERGIC RECEPTOR; ALPHA 2 ADRENERGIC RECEPTOR STIMULATING AGENT; ALPHA ADRENERGIC RECEPTOR; ANGIOTENSIN; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; BUCINDOLOL; DIURETIC AGENT; DOXAZOSIN; MOXONIDINE; NORADRENALIN; PRAZOSIN; RENIN;

ADRENERGIC SYSTEM; DISEASE COURSE; DRUG EFFECT; DRUG INDUCED DISEASE; DRUG MECHANISM; EDITORIAL; HEART FAILURE; HEART VENTRICLE REMODELING; HUMAN; HYPERTENSION; MORTALITY; NONHUMAN; PATHOPHYSIOLOGY; PRIORITY JOURNAL; SURVIVAL; SYMPATHETIC TONE; TREATMENT OUTCOME;

ADRENERGIC ALPHA-AGONISTS; ADRENERGIC ALPHA-ANTAGONISTS; ADRENERGIC BETA-ANTAGONISTS; ANIMALS; CATECHOLAMINES; DISEASE MODELS, ANIMAL; DISEASE PROGRESSION; HEART ATRIA; HEART FAILURE, CONGESTIVE; HUMANS; MICE; NOREPINEPHRINE; POLYMORPHISM, GENETIC; PRESYNAPTIC TERMINALS; RECEPTORS, ADRENERGIC, ALPHA-2; RENIN-ANGIOTENSIN SYSTEM; RESEARCH DESIGN; SYMPATHETIC NERVOUS SYSTEM; VASOCONSTRICTION; VENTRICULAR REMODELING;

EID: 0037027468     PISSN: 00097322     EISSN: None     Source Type: Journal    
DOI: 10.1161/01.CIR.0000037105.14195.B6     Document Type: Editorial

References (16)

1. 2-adrenoceptor subtypes prevents progression of heart failure. Circulation. 2002;106:2491-2496.
2. Cohn JN, Levine TB, Olivari MT, et al. Plasma norepinephrine as a guide to prognosis in patients with chronic congestive heart failure. N Engl J Med. 1984;311:819-823.
3. The Cardiac Insufficiency Bisoprolol Study (CIBIS-II): A randomized trial. Lancet. 1999;353:9-13.
4. Merit-HF Study Group. Effect of metoprolol CR/XL in chronic heart failure: Metoprolol CR/XL Randomised Intervention Trial in Congestive Heart Failure (MERIT-HF). Lancet. 1999;353:2001-2007.
5. 2-adrenergic receptors regulate sympathetic neurotransmission. Nature. 1999;402: 181-184.
6. Cohn JN, Archibald DG, Ziesche S, et al. Effect of vasodilator therapy on mortality in chronic congestive heart failure: Results of a Veterans Administration Cooperative Study (V-HeFT). N Engl J Med. 1986;314: 1547-1552.
7. ALLHAT Collaborative Research Group. Major cardiovascular events in hypertensive patients randomized to doxazosin vs chlorthalidone: The antihypertensive and lipid-lowering treatment to prevent heart attack trial (ALLHAT). JAMA. 2000;283:1967-1975.
8. Swedberg K, Bristow MR, Cohn JN, et al. Effects of sustained-release moxonidine, an imidazoline agonist, on plasma norepinephrine in patients with chronic heart failure. Circulation. 2002;105:1797-1803.
9. Coats AJ. Heart Failure 99: The MOXCON story, Int J Cardiol. 1999;71: 109-111.
10. The Beta-Blocker Evaluation of Survival Trial Investigators. A trial of the beta-blocker bucindolol in patients with advanced chronic heart failure. N Engl J Med. 2001;344:1659-1667.
11. Packer M, Bristow MR, Cohn JN, et al. The effect of carvedilol on morbidity and mortality in patients with chronic heart failure. N Engl J Med. 1996;334:1349-1355.
12. Packer M, Coats AJ, Fowler MB, et al. Effect on carvedilol on survival in severe chronic heart failure. N Engl J Med. 2001;344:1651-1658.
13. Campbell DJ, Aggarwal A, Esler M, et al. β-blockers, angiotensin II, and ACE inhibitors in patients with heart failure. Lancet. 2001;358: 1609-1610.
14. The SOLVD Investigators. Effect of enalapril on survival in patients with reduced left ventricular ejection fractions and congestive heart failure. N Engl J Med. 1991:325:293-302.
15. Lewis EJ, Hunsicker LG, Bain RP, et al. The effect of angiotensin converting enzyme inhibition on diabetic nephropathy. N Engl J Med. 1993;329:1456-1462.
16. Yusuf S, Sleight P, Pogue J, et al. Effects of an angiotensin-converting-enzyme inhibitor, ramipril, on cardiovascular events in high-risk patients. The Heart Outcomes Prevention Evaluation Study Investigators. N Engl J Med. 2000;342:145-153.